Vetigenics
Philadelphia
About Vetigenics
Vetigenics creates novel immunotherapies to treat cancer and other chronic conditions in dogs without the debilitating side effects. Our fully canine phage display platform, enables rapid isolation of unique antibody fragments (scFvs) or CANIBODIES™ to any antigen based binding affinity, functionality and developability. CANIBODIES™ are entirely generated from naïve, canine germline genes, don't require costly, time-consuming caninization and can be readily engineered into mAbs, BiTEs or CAR-T therapies. As a result, our therapies are designed for precision efficacy and lack of immunogenicity, not possible with other discovery technologies. Vetigenics is advancing three internally developed antibody products into the clinic with our 1st in dog studies starting during 1Q21
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $6.5M
- Funding stage: Seed
- Last round: Seed (Feb 2025)
- Website: vetigenics.com
- Phone: 2678752283
Industries & Categories
Biotechnology, Pet
Social Profiles
Canonical: https://fsome.com/organization/vetigenics-104573 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.